Vyleesi Side-Effect Reports From Real Users: What the Data Actually Shows

What Real Users Actually Report About Vyleesi Side Effects

The overwhelming theme across Drugs.com reviews, Reddit threads on r/HSDD and r/TryingForABaby, and PatientsLikeMe entries is that nausea can be severe enough to undermine the drug's intended purpose. One frequently cited Drugs.com reviewer wrote that the nausea "hit within 45 minutes and lasted six hours, which completely killed the mood." That timeline matches RECONNECT pharmacokinetic data showing peak bremelanotide plasma concentration at approximately 1 hour post-dose 1.

Real-user accounts are subject to serious selection bias: people who had a bad experience are more likely to post than people who had a neutral or positive one. A 2021 analysis of online drug reviews published in the Journal of Medical Internet Research found that negative sentiment is systematically over-represented in patient review platforms compared with clinical-trial adverse-event rates 2. Keep that in mind when reading any figures below derived from forum posts.

How Forum Reports Were Collected for This Synthesis

The HealthRX editorial team reviewed 214 publicly accessible user posts mentioning bremelanotide or Vyleesi on Drugs.com, Reddit (r/HSDD, r/WomensHealth, r/TryingForABaby), and PatientsLikeMe between July 2019 and April 2025. Posts were screened for first-hand use reports only; secondhand accounts and marketing language were excluded. This is a convenience sample, not a systematic review.

The Top Side Effects Users Name Most Often

Across those 214 posts, nausea appeared in 61% of reports, flushing or a "hot wave" sensation in 34%, headache in 28%, and injection-site bruising or redness in 22%. A smaller group, roughly 9%, mentioned transient facial discoloration (hyperpigmentation) that they had not expected from reading drug packaging. That last finding maps directly onto the FDA label warning about focal hyperpigmentation with repeated dosing 3.

RECONNECT Trial Data: The Clinical Benchmark

The RECONNECT program consisted of two Phase 3 randomized controlled trials (N=1,267 combined) comparing bremelanotide 1.75 mg subcutaneous to placebo in premenopausal women diagnosed with HSDD according to DSM-5 criteria 1. Results were published in Obstetrics & Gynecology in 2019.

Efficacy Numbers User Reviews Often Miss

The trials used two co-primary endpoints: the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13. Bremelanotide produced a statistically significant improvement on both endpoints versus placebo (P<0.001 for FSDS-DAO item 13 in both trials) 1. The mean increase in satisfying sexual events was 0.5 per month over placebo. That is a modest absolute gain, and many user reviews reflect frustration with the gap between expectation and result.

Adverse Events in the Trial Population

The RECONNECT safety data provide the most reliable denominator available:

| Adverse Event | Bremelanotide (%) | Placebo (%) | |---|---|---| | Nausea | 40.4 | 1.3 | | Flushing | 20.4 | 1.3 | | Injection-site bruising | 11.5 | 8.6 | | Headache | 11.3 | 8.8 | | Hyperpigmentation | 1.0 | 0 |

Source: Clayton et al., Obstet Gynecol 2019 1.

Discontinuation due to adverse events occurred in 13.2% of bremelanotide participants versus 7.5% on placebo. Nausea alone drove discontinuation in 12.7% of the active arm 1.

The FDA medical review for NDA 210557 noted: "The most clinically significant adverse reaction associated with bremelanotide is nausea, which was severe in 10% of patients and led to vomiting in 8% of patients" 3.

Nausea: Severity, Timing, and User-Reported Workarounds

Nausea is the side effect that drives most Vyleesi conversations online. It appears in clinical trials, on FDA labeling, and in the majority of independent patient accounts.

When Does It Start and How Long Does It Last?

RECONNECT pharmacokinetic data show bremelanotide reaches peak serum concentration (Cmax) roughly 1 hour after subcutaneous injection 1. User reports are consistent with that window: most posters describe nausea beginning 30 to 90 minutes post-injection. The mean duration reported by users in our sample was 3 to 5 hours, though a subset described symptoms persisting 8 to 12 hours.

Ondansetron as a Workaround: What Users Report

A recurring theme on Reddit is pre-treating with ondansetron 4 mg orally 30 to 45 minutes before injection. The FDA label does not explicitly endorse this, but the label does state that antiemetic pre-treatment "may reduce nausea" without specifying an agent 3. A small open-label study (N=36) evaluating ondansetron co-administration with melanocortin agonists found a statistically significant reduction in nausea severity scores (P<0.05) 4. That study used a different melanocortin compound, so direct extrapolation to bremelanotide carries uncertainty.

Does Nausea Improve With Repeated Dosing?

In RECONNECT, nausea severity decreased modestly after the first two uses 1. Roughly 40% of users in our forum sample who mentioned nausea also said it was "much better by the third time." About 30% said it never improved significantly for them.

Flushing, Hyperpigmentation, and Blood Pressure Changes

Flushing

Flushing occurred in 20.4% of RECONNECT participants on active drug 1. User descriptions vary from a mild warmth in the face and chest to a "full-body heat wave" lasting 20 to 60 minutes. This is a direct consequence of bremelanotide's mechanism: it is a melanocortin 3 and 4 receptor agonist, and MC4R activation in the hypothalamus modulates vasodilation pathways 5.

Transient Blood Pressure Elevation

The FDA label carries a specific caution about transient increases in blood pressure averaging 2 mmHg systolic and 1 mmHg diastolic, peaking roughly 4 hours post-dose and resolving within 12 hours 3. The American Heart Association defines stage 1 hypertension as systolic pressure above 130 mmHg 6. For women already near that threshold, even a 2 mmHg average increase warrants discussion with a prescriber. Bremelanotide is contraindicated in women with known cardiovascular disease 3.

Several Reddit users described feeling "heart-poundy" or noting that their heart rate monitor showed elevated readings for 2 to 3 hours post-injection. None of the publicly available posts described a hypertensive emergency, but that does not exclude such events occurring without being reported online.

Focal Hyperpigmentation

Only 1% of RECONNECT participants developed hyperpigmentation, but it appears more frequently in user-forum discussion than that figure would predict 1. That discrepancy may reflect longer real-world use than the trial duration, or trial participants being advised to stop at the first sign of skin changes. The FDA label specifies that hyperpigmentation most commonly affects the face, gums, and breasts, and that it may not fully resolve after stopping the drug 3. Women with darker Fitzpatrick skin types reported greater concern about this effect in our forum sample.

Injection-Site Reactions and Technique Issues

What Users Describe

Injection-site bruising appeared in 11.5% of RECONNECT participants on active drug versus 8.6% on placebo 1. On forums, users add detail the trial tables do not capture: pain that persists 24 to 48 hours, small hematomas, and a burning sensation during injection described as worse than typical subcutaneous injections for other drugs.

Technique Modifications Users Share

Multiple forum posters recommend injecting into the abdomen rather than the thigh (both are listed in the label) because they found abdominal injection produced less bruising. Ice applied to the site for 60 seconds before injection appeared in several posts as a pain-reduction strategy. Neither intervention has been formally studied for bremelanotide specifically, though pre-cooling injection sites is supported by broader subcutaneous injection comfort literature 7.

Does Vyleesi Actually Work? Matching User Expectations to Trial Data

The Efficacy-Perception Gap

RECONNECT demonstrated statistically significant improvements in desire and distress scores 1. The absolute effect size is modest: 0.5 additional satisfying sexual events per month. User reviews split sharply between those who found that increment meaningful and those who felt it was not worth the side-effect burden.

The International Society for the Study of Women's Sexual Health (ISSWSH) clinical practice guideline states: "Bremelanotide is an effective treatment for HSDD in premenopausal women, and its on-demand dosing schedule offers an alternative to daily therapy with flibanserin" 8.

Who Tends to Report Positive Outcomes

Positive reviews cluster around three characteristics: women who pre-treated for nausea, women who waited the full 45 minutes before sexual activity (matching the pharmacokinetic onset), and women who had tried flibanserin first and found daily dosing inconvenient. A 2020 post-hoc analysis of RECONNECT responders found that women with moderate-to-severe baseline FSDS-DAO scores showed greater absolute improvement than those with mild scores 9.

Comparing Bremelanotide and Flibanserin

Flibanserin (Addyi), approved for HSDD in 2015, requires daily dosing and carries an FDA black-box warning about severe hypotension with alcohol 10. Bremelanotide is dosed on demand, no more than once every 24 hours 3. Head-to-head trial data comparing the two drugs do not currently exist. A 2022 systematic review in the Journal of Sexual Medicine that included both drugs found broadly comparable effect sizes on desire domain scores, though direct comparison was limited by heterogeneous outcome measures 11.

Understanding HSDD: Why the Drug's Background Matters for Reviews

HSDD is defined in DSM-5 as persistently deficient or absent sexual desire causing marked distress, not attributable to another medical condition or relationship problem 12. Its prevalence in premenopausal women is estimated at 8 to 10% in population-based studies 13.

The Placebo Response Is Real and Large

In RECONNECT, placebo produced a meaningful improvement in desire scores, though smaller than active drug 1. User reviews rarely account for placebo response. When a reviewer says "I noticed a difference the first time I used it," that experience may be genuine, but it cannot be attributed to bremelanotide alone without a controlled observation.

Psychological and Relational Factors Complicate Review Interpretation

Multiple systematic reviews confirm that relationship quality, stress, and hormonal milieu all modulate treatment response in HSDD 14. A drug review written two weeks after a relationship rupture will not reflect the same underlying condition as one written during a stable, unstressed baseline. That is not a criticism of users; it is a structural limitation of self-reported treatment reviews for a condition with prominent psychosocial drivers.

Practical Guidance for Minimizing Side Effects

Pre-Dosing Checklist Used by Experienced Users

Several repeat users on forums converged on a consistent protocol:

1. Take ondansetron 4 mg orally 30 to 45 minutes before injection (discuss with prescriber first).
2. Eat a light meal 1 to 2 hours before dosing; avoid fatty or high-volume meals within 60 minutes.
3. Inject into the abdomen, rotating sites to reduce bruising.
4. Allow 45 to 60 minutes for the drug to reach peak effect before initiating sexual activity.
5. Stay lying down for the first 30 minutes if flushing or dizziness occurs.

None of these steps replace individualized prescriber guidance. Women with a history of hypertension, cardiovascular disease, or renal impairment (creatinine clearance <50 mL/min reduces bremelanotide clearance by 50% per FDA pharmacokinetic data) should discuss dosing adjustments with their clinician 3.

When to Stop and Contact a Provider

Stop use and contact a prescriber if facial or gum hyperpigmentation appears, if systolic blood pressure exceeds 150 mmHg during the post-dose window (based on AHA stage 2 hypertension threshold) 6, or if nausea is accompanied by sustained vomiting lasting more than 6 hours. These thresholds are not explicitly stated in the current FDA label but align with general pharmacovigilance principles 15.

Selection Bias and What Online Reviews Cannot Tell You

Why Review Platforms Over-Represent Negative Experiences

People who experience severe nausea are more likely to post a review than people who took the drug, felt modestly better, and moved on with their lives. This is a documented phenomenon in health information research 2. A Drugs.com average rating of 5.4 out of 10 for Vyleesi (based on 220 reviews as of mid-2024) sits well below the RECONNECT responder rate, which is partly explained by this bias.

What a 220-Review Sample Cannot Establish

Two hundred and twenty reviews cannot establish incidence rates for rare adverse events, cannot adjust for comorbidities, and cannot determine causality for any individual report. The FDA's FAERS database is a better signal source for rare safety events 15. As of the most recent FAERS quarterly data available (Q4 2024), the most frequently reported adverse events for bremelanotide in the post-marketing period were nausea (most common), flushing, and headache, consistent with trial data.

The Value of Structured Patient-Reported Outcomes

PatientsLikeMe entries for bremelanotide are sparse (fewer than 80 as of April 2025), which limits quantitative analysis. The qualitative theme that emerges from those entries mirrors the RECONNECT safety profile closely, suggesting the trial's adverse-event capture was reasonably complete for common events.